UnitedHealth Group FY2024 Financial Report: Revenue $400.3B Up 7.7%, Net Income $15.2B Declines 34%

Executive Summary

UnitedHealth Group, Inc. (Ticker: UNH), a leading health care and well-being provider, reported total revenues of $400.3 billion for FY2024, representing a 7.7% increase from the previous year’s $371.6 billion. Despite revenue growth, net earnings declined significantly by 34.2%, from $23.1 billion in FY2023 to $15.2 billion. The substantial decrease in net income is primarily attributable to a $7.1 billion loss on sale of South American assets, foreign currency translation impacts, and strategic portfolio adjustments. The company maintains a robust balance sheet with total assets of $298.3 billion and strong liquidity, although leverage increased due to debt issuance. Operating cash flow remained resilient at $24.2 billion, supporting ongoing dividend payments and share repurchases, though at a slightly lower level compared to prior periods. This report provides a detailed analysis of financial performance, key ratios, risk factors, and investment implications for stakeholders.

Key Metrics

Management Discussion and Analysis

UnitedHealth Group’s FY2024 results reflect continued top-line growth driven by robust premium and services revenues across its segments. The 7.7% revenue increase signifies expanding market share and diversified health offerings. However, the net income decline highlights challenges including strategic asset disposals, foreign currency impacts, and increased debt levels. The sale of South American operations resulted in a $7.1 billion loss, significantly impacting overall profitability. Despite this, the company’s core U.S. operations remain strong, supported by high-margin Medicare and commercial plans, and investment in digital health technologies. Liquidity remains adequate with over $25 billion in cash and equivalents, although leverage has increased due to recent debt issuances to fund acquisitions and share repurchases. The company continues to prioritize shareholder returns via dividends and buybacks, with a total payout of $2.6 billion in dividends and $8.9 billion in repurchases during FY2024. Strategic focus on modernizing healthcare delivery and expanding digital capabilities is expected to sustain growth long term.

Income Statement Analysis

Revenues increased by 7.7%, primarily from growth in premiums (USD 308.8 billion) and services (USD 36 billion). The gross margin, calculated as (Revenues – Medical Costs) / Revenues, remained stable at approximately 34%, indicating effective cost management. Operating income was USD 32.3 billion, slightly lower than FY2023 due to the $8.3 billion loss on sale of subsidiaries and higher operating expenses. Net income fell sharply by 34.2%, from USD 23.1 billion to USD 15.2 billion, mainly reflecting the $7.1 billion loss on sale, foreign currency translation losses, and increased interest expenses. Earnings per share (diluted) declined from USD 23.86 to USD 15.51, a decrease of 35.0%, demonstrating the impact of reduced net income on shareholder value.

Balance Sheet Analysis

Assets grew by 9.0%, reaching USD 298.3 billion, driven by increases in goodwill (USD 106.7 billion) and intangible assets (USD 23.3 billion). Cash and cash equivalents totaled USD 25.3 billion, down slightly from USD 25.4 billion. Accounts receivable increased to USD 22.4 billion, reflecting higher premium and service billings. Debt levels increased with long-term debt rising to USD 72.4 billion, partly funded by new bond issuances. Equity increased modestly by 4.2%, totaling USD 98.3 billion, supported by retained earnings and comprehensive income. Liquidity remains healthy, but increased leverage warrants monitoring for long-term financial stability.

Cash Flow Analysis

Net cash provided by operating activities was USD 24.2 billion, a decrease from USD 29.1 billion in FY2023, mainly due to higher working capital needs and strategic asset sales. Capital expenditures were USD 3.5 billion, consistent with prior periods, aimed at expanding digital infrastructure. Cash paid for acquisitions and strategic investments was USD 13.4 billion, including the divestment proceeds from South America. Financing activities resulted in net inflows of USD 6.0 billion, primarily from bond issuance, offset by dividend payments of USD 2.6 billion and share repurchases of USD 8.9 billion. The company’s balance sheet remains strong, with ample liquidity to support growth initiatives and shareholder returns.

Ratios & DuPont Analysis

The net profit margin declined from 6.2% in FY2023 to 3.8% in FY2024, mainly due to the non-recurring sale loss. Return on assets (ROA) decreased from 8.4% to 5.1%, reflecting lower net income relative to total assets. Return on equity (ROE) fell from 24.5% to 15.4%, impacted by the profit decline and increased leverage. Asset turnover remained stable at approximately 1.34, indicating consistent utilization of assets to generate revenue. The equity multiplier increased from 2.9 to 3.0, reflecting higher leverage. Overall, the DuPont analysis shows pressure on profitability but stable efficiency and slightly increased leverage, supporting a cautious outlook.

Risk Factors

Key risks include regulatory and legal uncertainties, including ongoing investigations and potential penalties related to Medicare and Medicaid compliance. Market competition and pricing pressures in health insurance segments could impact margins. Operational risks from cybersecurity threats, system disruptions, and cyberattacks remain significant. Macroeconomic factors such as inflation, interest rate fluctuations, and currency exchange risks, particularly with foreign asset disposals, also pose challenges. Additionally, portfolio adjustments and asset sales may result in short-term volatility and strategic realignment risks.

Notes & Additional Commentary

The FY2024 results reflect strategic portfolio restructuring, including the substantial sale of South American operations, which contributed a USD 7.1 billion loss. The foreign currency translation losses of USD 855 million further impacted comprehensive income. The company’s ongoing investments in digital health initiatives and infrastructure are expected to enhance competitive positioning. The increased leverage and debt levels require close monitoring for long-term creditworthiness. Unusual items such as impairment losses from asset disposals underscore the importance of strategic agility and risk management.

Investment Implications

UnitedHealth Group’s revenue growth remains solid, supported by diversified healthcare offerings. However, profitability has experienced downward pressure due to non-recurring losses and strategic asset sales. Short-term opportunities include capitalizing on digital health growth and operational efficiencies. Long-term risks involve macroeconomic volatility, regulatory challenges, and potential adverse effects from high leverage. The company’s strong cash flow supports shareholder returns, but investors should remain cautious regarding profit margins and strategic restructuring impacts. Overall, UNH offers a resilient core business with opportunities for growth, balanced by operational and financial risks that warrant careful monitoring.